CTI BIOPHARMA

At CTI, we are resolute in our commitment to deliver new medicines to patients with blood-related cancers who have limited treatment options. With our deep hematology-oncology expertise and sense of urgency, we are motivated to shift the treatment paradigm for blood-related cancers... At CTI, we are all deeply connected to each other and our work, united in our quest to improve the lives of patients and their families facing blood-related cancers. Our team holds diverse expertise advancing hematology, oncology and rare disease therapies for patients worldwide, and shares one vision for transforming the future of cancer treatment through scientific excellence and compassion... We are a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO® (pacritinib), a JAK2, ACVR1, and IRAK1 inhibitor,..

Also known as: CTI, CTI BIOPHARMA CORP.

Primary location: Seattle United States